10-Q: eXoZymes Inc. Q1 2026 Financials Show Increased R&D Spend

eXoZymes Inc. reported a net loss of $2.37 million for Q1 2026, with a significant increase in R&D costs, while cash reserves decreased by over 50%.

Summary

• eXoZymes Inc. reported a net loss of $2,370,247 for the first quarter ended March 31, 2026, compared to a net loss of $1,856,421 for the same period in 2025.
• Total operating costs increased by 22.4% to $2,386,974, driven by a 95.0% surge in research and development (R&D) costs.
• General and administrative costs decreased by 8.0% to $1,265,966, primarily due to lower professional fees and investor relations expenses.
• Cash and cash equivalents significantly decreased by 52.5% to $1,444,562 as of March 31, 2026, from $3,039,343 as of December 31, 2025.
• The company has a material weakness in internal control over financial reporting, with ongoing remediation efforts.
• eXoZymes Inc. is pursuing a proposed public offering of approximately $15 million to fund ongoing product development and commercialization.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, significant cash burn, and explicit mention of substantial doubt regarding the company's ability to continue as a going concern, despite ongoing efforts to secure capital.

Positives

• Decrease in professional fees by 47.8% to $277,679, indicating improved operational efficiency or reduced external support needs.
• Decrease in general and administrative costs by 8.0% to $1,265,966.
• The company has met development milestones for its exclusive license agreement with The Regents of the University of California.
• The company has a shelf registration statement allowing for up to $50.0 million in future securities offerings.

Negatives

• Net loss increased by 27.7% to $2,370,247 for the quarter ended March 31, 2026.
• Cash and cash equivalents decreased by 52.5% to $1,444,562, raising concerns about near-term liquidity.
• Research and development costs increased by 95.0% to $1,121,008, significantly impacting the net loss.
• The company has a material weakness in internal control over financial reporting.
• The company states that its existing working capital is not sufficient to fund operations for a full twelve-month period.

Risks

• The company's ability to continue as a going concern is subject to doubt due to anticipated funding shortfalls and its pre-revenue status.
• Changes to U.S. tariff and import/export regulations could adversely affect the business, financial condition, and results of operations.
• Government actions on tariffs, trade policies, immigration policies, and research grants could impede the ability to conduct research and raise capital.
• The company's technologies may never come to fruition, might not reach commercial viability, or may not gain widespread acceptance.
• Technologies may fail to receive necessary regulatory approvals.
• An economic recession could impact the general business environment and capital markets, affecting the company.
• The company is subject to the terms of its exclusive license agreement, including potential milestone payments and termination rights.

Future Outlook

The company is pursuing a proposed public offering of approximately $15 million to fund ongoing product development and commercialization activities. The company also intends to pursue additional grants and may seek institutional or bank financing, and the sale or licensing of intellectual property. However, there are no committed sources of additional financing, and the company's ability to continue operations depends on securing additional financial resources or achieving profitable operations.

Management Comments

• Management believes that eXoZymes technology is a differentiated and unique synthetic biology platform that will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than typical methods.
• Management believes that there remains substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and the Company's pre-revenue status.
• Management considers the grants receivable as of March 31, 2025, to be fully collectible, based on historical experience with the Federal Government of the United States of America.

Industry Context

StockSavvy.ai notes that eXoZymes operates in the highly competitive and capital-intensive biotechnology sector, where significant R&D investment is crucial for innovation. The increased R&D spend, while contributing to the current net loss, is a necessary step for developing novel synthetic biology platforms and potential commercial products. The company's focus on sustainable and environmentally friendly production methods aligns with growing industry trends.

Comparison to Industry Standards

• The net loss per common share of $(0.28) for Q1 2026 is higher than the $(0.22) reported in Q1 2025, indicating a worsening financial performance on a per-share basis.
• The significant increase in R&D costs (95.0%) is typical for pre-revenue biotechnology companies aiming to develop proprietary technologies, but it outpaces the growth in general and administrative cost reductions.
• The substantial decrease in cash and cash equivalents (52.5%) highlights the burn rate common in early-stage biotech firms, necessitating continuous fundraising efforts.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened litigation that would have a material adverse effect on its business.

Related Party Transactions

• Outstanding payables to MDB Capital Holdings, LLC were $13,406 as of March 31, 2026, and $5,330 as of December 31, 2025. These are non-interest bearing.
• Public Venture, LLC, a subsidiary of the Company's largest shareholder, MDB Capital Holdings, LLC, plans to serve as an underwriter for a proposed public offering.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, but also potential upside if the company's technology development is successful. The proposed $15 million offering could impact share price.
• Employees: Increased R&D spend may lead to hiring, but the going concern doubt and cash burn could create uncertainty.
• Creditors: The company's ability to meet long-term obligations depends on securing additional financing.
• Partner Companies/Clients: Government policy changes regarding tariffs and research grants could indirectly affect their ability to work with eXoZymes.

Next Steps

• Continue product development and commercialization activities.
• Pursue additional grants and non-dilutive funding opportunities.
• Potentially seek institutional or bank financing.
• Explore sale or licensing of intellectual property.
• Complete the proposed public offering of approximately $15 million, subject to market conditions and definitive agreements.

Key Dates

Recommendation

The company is in a pre-revenue, development stage with significant cash burn and a stated doubt about its ability to continue as a going concern. While the proposed capital raise and ongoing R&D are positive steps, the inherent risks and current financial performance warrant a cautious 'hold' approach until greater clarity on funding and commercialization is achieved.

Keywords

eXoZymes, 10-Q, Quarterly Report, Biotechnology, Synthetic Biology, Research and Development, Net Loss, Cash Flow